Are you referring to HIV and the BLA that cannot seem to get filed for whatever reason? We need primary endpoints to be hit for our current trials and THAT will move the SP higher. No one trusts that the clinical portion of the HIV BLA will get filed in a timely manner, which is why the SP doesn't move when they filed other parts of it.

I hope that the clinical portion of the BLA DOES get filed in Q1, but history isn't on our side for that right now.

I do not believe that one big investor who touts Vyrologix will move the SP higher.